» Articles » PMID: 37500825

Incidence, Prevalence, and Global Burden of Schizophrenia - Data, with Critical Appraisal, from the Global Burden of Disease (GBD) 2019

Abstract

Schizophrenia substantially contributes to the burden of mental disorders. Schizophrenia's burden and epidemiological estimates in some countries have been published, but updated estimates of prevalence, incidence, and schizophrenia-related disability at the global level are lacking. Here, we present the data from and critically discuss the Global Burden of Diseases, Injuries, and Risk Factors Study data, focusing on temporal changes in schizophrenia's prevalence, incidence, and disability-adjusted life years (DALYs) globally. From 1990 to 2019, schizophrenia raw prevalence (14.2 to 23.6 million), incidence (941,000 to 1.3 million), and DALYs (9.1 to 15.1 million) increased by over 65%, 37%, and 65% respectively, while age-standardized estimates remained stable globally. In countries with high socio-demographic index (SDI), both prevalence and DALYs increased, while in those with low SDI, the age-standardized incidence decreased and DALYs remained stable. The male/female ratio of burden of schizophrenia has remained stable in the overall population over the past 30 years (i.e., M/F = 1.1), yet decreasing from younger to older age groups (raw prevalence in females higher than males after age 65, with males having earlier age of onset, and females longer life expectancy). Results of this work suggest that schizophrenia's raw prevalence, incidence, and burden have been increasing since 1990. Age-adjusted estimates did not reduce. Schizophrenia detection in low SDI countries is suboptimal, and its prevention/treatment in high SDI countries should be improved, considering its increasing prevalence. Schizophrenia sex ratio inverts throughout the lifespan, suggesting different age of onset and survival by sex. However, prevalence and burden estimates for schizophrenia are probably underestimated. GBD does not account for mortality from schizophrenia (and other mental disorders, apart from anorexia nervosa).

Citing Articles

Leveraging deep neural network and language models for predicting long-term hospitalization risk in schizophrenia.

Bao Y, Wang W, Liu Z, Wang W, Zhao X, Yu S Schizophrenia (Heidelb). 2025; 11(1):35.

PMID: 40044707 PMC: 11882783. DOI: 10.1038/s41537-025-00585-2.


Striatal dopamine D2/D3 receptor regulation of human reward processing and behaviour.

Osugo M, Wall M, Selvaggi P, Zahid U, Finelli V, Chapman G Nat Commun. 2025; 16(1):1852.

PMID: 39984436 PMC: 11845780. DOI: 10.1038/s41467-025-56663-7.


Reduced temporal variability of cortical excitation/inhibition ratio in schizophrenia.

Racz F, Farkas K, Becske M, Molnar H, Fodor Z, Mukli P Schizophrenia (Heidelb). 2025; 11(1):20.

PMID: 39966406 PMC: 11836122. DOI: 10.1038/s41537-025-00568-3.


Sleep duration and its associated factors in schizophrenia patients: a large-scale cross-sectional survey.

Dong M, Liao D, Tan W, Lin H, Wang S BMC Psychiatry. 2025; 25(1):123.

PMID: 39948526 PMC: 11827318. DOI: 10.1186/s12888-025-06581-1.


Optimising Aripiprazole Long-Acting Injectable: A Comparative Study of One- and Two-Injection Start Regimens in Schizophrenia with and Without Substance Use Disorders and Relationship to Early Serum Levels.

Trovini G, Lombardozzi G, Kotzalidis G, Lionetto L, Russo F, Sabatino A Int J Mol Sci. 2025; 26(3).

PMID: 39941162 PMC: 11818917. DOI: 10.3390/ijms26031394.


References
1.
Correll C . [Pharmacotherapy of schizophrenia]. Nervenarzt. 2020; 91(1):34-42. DOI: 10.1007/s00115-019-00858-z. View

2.
Correll C, Solmi M, Veronese N, Bortolato B, Rosson S, Santonastaso P . Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls. World Psychiatry. 2017; 16(2):163-180. PMC: 5428179. DOI: 10.1002/wps.20420. View

3.
Firth J, Solmi M, Wootton R, Vancampfort D, Schuch F, Hoare E . A meta-review of "lifestyle psychiatry": the role of exercise, smoking, diet and sleep in the prevention and treatment of mental disorders. World Psychiatry. 2020; 19(3):360-380. PMC: 7491615. DOI: 10.1002/wps.20773. View

4.
Vancampfort D, Stubbs B, Mitchell A, De Hert M, Wampers M, Ward P . Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis. World Psychiatry. 2015; 14(3):339-47. PMC: 4592657. DOI: 10.1002/wps.20252. View

5.
Vancampfort D, Correll C, Galling B, Probst M, De Hert M, Ward P . Diabetes mellitus in people with schizophrenia, bipolar disorder and major depressive disorder: a systematic review and large scale meta-analysis. World Psychiatry. 2016; 15(2):166-74. PMC: 4911762. DOI: 10.1002/wps.20309. View